Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (4216)	7/10/1998 5:36:00 PM
From: B.REVERE	Read Replies (2) \| Respond to of 9523

Anthony, picked up this post from Yahoo board who credits analyst from Everen Securities for the logic in why pfe turned around mid-afternoon and stayed strong throughout the day. Made sense to me that mgmt. would want to frontload expenses from r&d into this quarter to protect third quarter's earnings. Comments anyone?<- Previous Next -> Message 14854 of 14873 Reply Pfizer profits higher than reported moneymoover Jul 10 1998 3:35PM EDT Just saw a report that Pfizer actually had a 59 cent profit per share. Management reduced this figure by moving more R&D expense into this quarter's report. This accounted for about 6 cents of the 12 cent reduction. Another 6 cents in costs applied were attributed to a higher tax rate and "other deductions". A couple of concerns not discussed here as yet- 1. What happens to the market if we see a political change in Congress after this falls' election? 2. What impact if any on the market and January 2000 Leaps from the Y2K issue? As you old-timers know I am long on Pfizer. However, I also made some money with some call options bought on Pfizer a couple weeks ago. Any thoughts as to where we should be buying back in again on call options after a pull back? Moneymoover

To: Anthony Wong who wrote (4216)	7/10/1998 6:40:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Jul 10, 1998 (6:17 PM ET) - The Motley Fool Evening News Erectile dysfunction treatment developer Vivus Inc. (Nasdaq:VVUS - news) fell $1 7/32 to $6 1/2 after reporting a second quarter loss of $0.55 a share (before charges) compared with earnings of $0.28 for the same year-ago period. Analysts had expected a loss of $0.45. Although Vivus shares rose on Pfizer's (NYSE:PFE - news) coattails, thanks to investors who thought the company would benefit from heightened interest in Pfizer's Viagra impotence pill, domestic demand for Vivus' MUSE product has dropped about 70% since the launch. Second quarter revenues totaled $16 million, down from $33.5 million in the year-earlier period and $26.5 million in Q1. There was a ray of sunshine abroad for Vivus, though. Revenues rose to $9.8 million from $2 million in the preceding quarter as the company's international marketing partners, Janssen Pharmaceutica and Astra AB (NYSE:A - news) , began launching MUSE in various countries. Of course, Viagra has yet to be approved for marketing globally, so Vivus hasn't had to face competition overseas.

To: Anthony Wong who wrote (4216)	7/10/1998 7:13:00 PM
From: Anthony Wong	Respond to of 9523

IMS Health Unit Gets 3-Yr, $800,000 Pact From Pfizer Korea July 10, 1998 5:48 PM ATLANTA (Dow Jones)--IMS Health Inc.'s (RX) Sales Technologies/Walsh unit signed a three-year, $800,000 contract to provide sales force automation services to Pfizer Inc.'s (PFE) Pfizer Korea unit. In a press release Friday, Sales Technologies said Pfizer will use its Premiere application as a possible regional solution for field support systems. Pfizer is a research-based health care company. IMS Health provides information solutions to the pharmaceutical and healthcare industries.